Life Sciences Archive » April, 2012

Life Sciences - April, 2012

290 articles

• Becton Asks High Court To Refuse Retractable's IP Appeal
• Senate Panel Fattens USDA Food Inspection Budget
• High Court Won't Weigh Suit Over Generic Reglan Labeling
• Ex-Pfizer Saleswoman Says She Was Fired Over Pregnancy
• Warner Chilcott Weighs Sale To Boost Shareholder Value
• Losing The 'Empty Chair' At Trial
• Judge OKs Mylan's Acne Generic But Keeps Patent Intact
• Ex-Squire Sanders IP Attorney Jumps To Carr & Ferrell
• Q&A With Paul Hastings' Gerald Flattmann
• Jones Day, Brown Rudnick Aid Hologic In $3.7B Gen-Probe Buy
• Conceptus Shuns $19M IP Deal As Rival Pulls Contraceptive
• Darvocet Plaintiffs Can't Take Generics Dismissal To 6th Circ.
• Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent
• Merck Wins Patent Rights Suit Over Singulair Imports
• Otsuka Slaps Amneal With IP Suit Over Generic Abilify
• Vivus' Erectile Dysfunction Drug Stendra Wins FDA Approval
• China Cord Blood Closes $65M Debt Financing With KKR
• Treasury Fines Medical Equipment Maker Over Iran Shipment
• HHS Has Final Say On Medicare Device Coverage: 4th Circ.
• FDA Chews Out Angiomax Maker Over Promo Materials
• Warner Chilcott Targets Ranbaxy's Osteoporosis Generic
• New FDA Rule Broadens Scope Of Clinical Investigator Bans
• Q&A With Gibson Dunn's Mark Perry
• Subleasing — More Than Meets The Eye
• Judge Hints At Collusion In $12M Boiron False Ad Settlement
• FDA Advisory Panel Backs Cameron's New Defibrillators
• High Court Asked To Review Antitrust Standing Rule
• FDA Exploring '1-Page Solution' to Med Guide Size
• Saint-Gobain Not Owed Higher Infringement Bar, SG Says
• Medical Co. Launches $90M Suit Over Mad Cow Contamination
• Health Law Challengers Make One More Plea On Tax Issue
• SEC Sets Sights On Bristol-Myers In Foreign Bribery Crackdown
• Dialysis Co. Says Prior Deal Bars Some FCA Claims
• King & Spalding Nabs 2 Cadwalader Pharma Litigation Pros
• Abbott Again Moves To Block Generic Version Of Zemplar
• Q&A With WilmerHale's Lia Der Marderosian
• 13 States Want In On $90M Medicaid Suit Against Healthpoint
• FDA Doesn't Have The Discretion It Thought It Had
• Operationalizing Law Department Performance Metrics
• Judge Asks GSK To Tweak Details In $10.4M Paxil Settlement
• FTC Loses Androgel Pay-For-Delay Appeal In 11th Circ.
• Watson To Pay $5.6B For Generic-Drug Maker Actavis
• Pfizer Off-Label Marketing Suit Pushed Toward Dismissal
• Icahn Ditches Amylin Suit After Chat With CEO
• Purdue Seeks To Stop Watson's Reformulated Oxy Generic
• Pitt's Award Doubled To $74M For Varian's Willful Infringment
• FDA User Fee Bill Clears 1st Legislative Hurdle
• Amgen To Shell Out $669M For Turkish Drugmaker
• Cellectis Faces Rival's 10th Genome Engineering IP Suit
• Q&A With Morgan Lewis' Randall Sunberg
• Boston Scientific Reports Death From Defibrillator Glitch
• The Mayo Test: Impact On Personalized Medicine And Beyond
• Ardea Sued Over $1.3B AstraZeneca Deal
• Research Co. Makes Peace With FDA Over Suspect Drug Tests
• FDA's Nanotech Safety Rules May Not Help Cos. Avoid Risk
• Darvocet Judge Won't Seek States' Input On Lilly Liability
• CMS Rejects HHS Call For Off-Label Avastin Endorsement
• FDA User Fee Bill Faces 1st Test In Senate Panel Vote
• ViroPharma Loses Bid To Block Generic Vancocin
• Roche Recalls Potentially Faulty Heart Attack Test Tools
• Sun Pharma, Mylan Enter Growing Pool Of Zyprexa Generics
• Innisfree Snags Takeover Pro From Sullivan & Cromwell
• Merck Ducks Missouri Vioxx Claims Linked To Settlements
• Pain Drug Co. Treated To Shareholder Suit Over Exec's Exit
• Actos May Increase Bladder Cancer Risk, Health Canada Warns
• Q&A With Fish & Richardson's Jonathan Singer
• Mylan Loses Bid To Block Teva's Provigil Market Rights
• A Bitter Pill: Personal Liability For Health Care Execs
• InfuPharma Targets Insurer For Avastin Defense
• Ill. Dad Slaps Cochlear Implant Maker With Class Action
• Trustees Report Leads To Calls For Medicare Reform
• Fired CR Bard Exec Sues Over Age Bias
• FDA Unveils Rules For Nanotech In Food, Cosmetics
• Standstills And No Shops: A Potentially Dangerous Mix
• Med Industry Presses FDA To Modernize Clinical Trial Rules
• BVF Partners Pursues Appeal Over Genetics Co. Sale
• Doctors Slam Federal Stem Cell Research Funding In DC Circ.
• FDA Bolsters Post-Market Scrutiny Of Drugs
• OrbiMed Debuts $222M Israeli Life Sciences Venture Fund
• Q&A With King & Spalding's Seth Lundy
• FDA Spotlights 'Prominent Risks' Of Cameron Defibrillator
• Judge Expedites Icahn's Suit Over $3.5B Amylin Takeover Bid
• Merck Escapes High Court Hearing In $26M Vioxx Suit
• Davis Wright Adds Ex-MoFo Patent Pro In San Fran
• Apotex Sues Pfizer, UCB, Others Over Blood Pressure Meds
• Mayer Brown Reps Nestle On $12B Purchase Of Pfizer Unit
• Between You And Me: FDA Comments Not Disclosure Events
• PPACA: Illuminating The Dark Side Of Health Care
• Covington Aids AstraZeneca In $1.3B Ardea Biotech Buy
• Graceway's Ch. 11 Plan Gets Nod As Judge Quells IRS Worries
• Enzo Targets Siemens Over Viral Load Testing Patent
• Anti-Mensing Bill Could Topple FDA's Generics Framework
• Case Study: Caraco V. Novo Nordisk
• How They Won It: Fish & Richardson Triumphs For Mayo
• Wyeth Hit With $4M Jury Verdict In Prempro Suit
• EU Committee Backs Bristol, Astra Diabetes Drug Forxiga
• FDA Warns Of More Eye Infections Related To Recalled Dye
• Novartis Agrees To Stricter Safety Measures For MS Drug
• Warning! FDA Is Flexing Its PMR Enforcement Muscle
• Aspen Pays $263M For GSK's Zantac, Other OTC Drugs
• Judge Balks At ViroPharma's Bid To Halt Vancocin Generics
• FDA Head Defends Tech Upgrade Progress To Senate Panel
• Fed. Circ. Nixes Inventor's Anti-Coagulant Patent App
• Generics Industry's Drug Shortage Plan Wins FDA Support
• McDermott Snags Former McGuireWoods Life Sciences Chair
• Judge OKs $321.6M Fine Against Merck For Vioxx Marketing
• Fentanyl Patches Can Be Deadly To Children, FDA Warns
• PETA Agrees To Put Down Merck Securities Suit
• Elan, Pfizer Didn't Hype Alzheimer's Drug, 2nd Circ. Hears
• Ivera Targets Catheter Connections Over Medical Device IP
• J&J Faces Canadian Suit Over Surgical Mesh Complications
• CIT Upholds Applikon's Win In Bioreactor Duty Fight
• FDA: Shining A New Light On Benefit-Risk Analysis
• Biotech Co. Human Genome Rejects $2.6B Bid From GSK
• J&J's $21B Synthes Buy Gets EU Nod After Divestiture
• New Bill Would Let Generics Makers Update Own Labels
• FDA Rejects Approval Of Change To Nuvo Anesthetic Cream
• Lupin Pushes Fed. Circ. To Reconsider Fortamet Injunction
• House Mulls Controversial FDA Mission Change
• Jury Sides With Pitt In $37M Radiation Patent Row With Varian
• Industry Drug-Tracking Idea Not Worth The Cost, FDA Says
• Mylan Fights FDA On Teva's Provigil Market Rights
• Merck Chalks Up 2nd Fosamax Trial Win In NJ
• Endo Pharma Freed From 14 Suits In Darvocet, Darvon MDL
• Pfizer Sells Land Near Old Brooklyn Factory To Local Investors
• Medical Lab Rep Still Shunting Sales To Rival, Suit Says
• Senate Bill Expands Pediatric Drug Regulation, Incentives
• Roche Gives Up On $6.2B Hostile Bid For Illumina
• Limiting The Impact Of Prometheus
• Docket Diving: Strategic Uses Of Online Docket Info
• Lilly Sues Apotex Over Lung Cancer Drug Patent
• Generics' High Court Win Opens New Battleground With Pharmas
• GSK Pays $2.6M To Exit Idaho Drug Price-Fixing Suit
• Fed. Circ. Again Eyes Ban On Lupin's Generic Fortamet
• Pfizer Nears $9B Sale Of Baby Formula Unit To Nestle
• Report Knocks FDA For Lagging On Critical IT Upgrades
• Hospira Drug Shortage Harmed Vitamin-Deficient Patients: Suit
• Drugmakers Spar Over Clinical Trial Rules For Biosimilars
• J&J Sued Over Death Of Baby Who Took Recalled Tylenol
• JPML Consolidates Zoloft Birth Defect Suits In Pa.
• Paraplegic's Medtronic Suit Preempted, Split 9th Circ. Rules
• Pay-For-Delay Suits Against Pfizer Consolidated In Tenn.
• Merck To Face Propecia Sexual Dysfunction MDL
• Cozen O'Connor Fattens IP Practice With Duane Morris Team
• FDA Warns Dental Device Maker Over Unapproved Use Ads
• High Court OKs Patent Use Challenges By Generic Drug Cos.
• FTC: Weeding Through Substantiation Of Health Care Ads
• Case Study: Marine Polymer V. HemCon
• Judge Finds No New Misconduct By Pfizer In Celebrex Suit
• High Court Considers Drug Sales Reps' OT Status
• Merck Betting Up To $1B On Endocyte's Cancer Treatment
• Dey Didn't Infringe Asthma Drug Patent, Fed. Circ. Rules
• Allergan Eyes Generics Makers In Glaucoma Patent Row
• Fed. Circ. Says Hard Facts Key To Obviousness Rulings
• Keller and Heckman Makes Inroads In EU With New Paris Office
• Fed. Circ. Won't Protect Bayer From Generic Yasmin
• Sanofi Accuses FedEx Of Wrecking $7M Vaccine Shipment
• Learning From Omeros' FCA Suit
• UCB Targets Covidien Unit Over Ritalin Patent
• Genzyme Negligence Suit Won't Get High Court Hearing
• High Court Refuses Pfizer Appeal Over Novartis Hemophilia IP
• Medicis, Perrigo Reach Licensing Deal on Loprox Shampoo
• Drug Reps' OT Case To Take Center Stage At High Court
• U. Of Kansas Wins Inventor Credit For NIH Cancer Drug
• ViroPharma Sues FDA To Block Generic Vancocin Release
• Cetero Gets Nod To Auction Assets In Ch. 11
• Texas Agency Gives Go-Ahead To Experimental Stem Cell Use
• FDA Warns Ferring, Says Firmagon Sales Pitch Is Misleading
• Deleted Billing Code Hobbled Orthotics Sales, Co. Contends
• Astellas Unit, Pfizer Sue To Bar Roxane's Generic Tarceva
• Purdue Tries To Knock Out Generic OxyContin ANDA
• Antitrust Challenges To FDA Citizen Petitions: Part 2
• Olympus Faces $2M Fine For Accounting Scandal
• FDA Overstepped In Pet Drug Case, Groups Tell 11th Circ.
• Merck Drugs Tied To Lingering Sex Disorders, FDA Warns
• FDA Experts Push For Wider Anti-Overdose Drug Availability
• Investor Sues To Halt Genstar's $400M Buy Of Research Co.
• Becton Dickinson Loses Bid To Trademark Blood Tube Cap
• Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid
• US Calls For J&J Exec's Testimony In FCA Kickbacks Case
• FDA Disputes AstraZeneca's Seroquel Exclusivity Claims
• Trading Secrets: An Unwise Move In The Electronic Age
• EU Approves Abbott's Humira For Ulcerative Colitis Use
• Board Pushes For Medical Device Cybersecurity Oversight
• Depomed Targets Impax, Par Over Generic Epilepsy Drug
• FDA Warns ThyssenKrupp Over Wheelchair Lift Defects
• FDA Asks Drug Cos. To Curtail Antibiotics In Livestock Feed
• High Court Again Asked To Mull Patent Evidence Limits
• Fed. Circ. Allows Attys' Fees For Time-Barred Vaccine Claims
• Scottsdale Recoils At Coverage For Defective Wrinkle Meds
• Bayer Can't Sidestep Men's Vitamin False Ad Suit
• Takeda Sales Manager Urges 4th Circ. To Save FCA Case
• Wellbutrin Antitrust Class Survives Bid To Nix Cert.
• J&J Fined $1.2B In Ark.'s Risperdal Marketing Suit
• Gilead Ducks Reinstatement, Back Pay Claims In FCA Suit
• Is Mayo V. Prometheus Really A Game Changer?
• Sidley Helps Takeda With $800M Gout Drugmaker Buy
• Medical Product Maker HemCon Files For Ch. 11
• J&J Unit Loses In Ark.'s Risperdal Marketing Suit
• 2nd Circ. Clears Way For Asbestos Suits Against Pfizer
• Abbott Hit With Shareholder Suit Over Depakote Marketing
• FDA Considers Making Anti-Overdose Drug More Accessible
• 1st Circ. Lets Feds Join Arguments In Pfizer FCA Suit
• FDA Adds Blood Clot Risk Data To Birth Control Labels
• FDA Rejects ViroPharma Testing Plea, OKs Generic Vancocin
• FDA Backs Medtronic Heart Device For Many More Patients
• Journal Won't Pull Article Linking St. Jude Wires To Deaths
• Health Law Will Add $340B To Deficit, Medicare Trustee Says
• Sullivan Aids Amgen On $315M Kidney Drugmaker Buy
• Latham Guides Genstar In $400M Pharma Research Co. Buy
• Shearman Reps Corning In $730M Labware Unit Buy
• New VA Restrictions On Drug Co. Detailing Activities
• Teva Says Wyeth Patent Deal Doesn't Step On Antitrust Law
• Icahn Sues Amylin Over Alleged $3.5B Takeover Bid
• Former Orthofix VP Cops To Paying Kickbacks
• Patton Boggs Takes On 4-Atty IP Team From SNR Denton
• Fosamax Expert Grilled Over Financial Ties To Merck
• ABA Prez Slams Obama's Remarks On High Court Health Ruling
• Ex-Ferring Workers Made $43M On Stolen Drug Info, Suit Says
• FDA Picks 3 Kidney Devices For Fast-Track Approval Program
• Inequitable Conduct Ruling Survives Sanofi Fed. Circ. Appeal
• Jury Awards $225K For Jaw Decay From Novartis Bone Drug
• Eye Laser Maker Clears Up $10.6M Case Over Botched Research
• Whistleblower Pushes For New Look At Abbott Stent Case
• Takeaways From HHS Pharma Compliance Roundtable
• Continuing The Trend: Biomet's FCPA Settlement
• Investors Accuse Chelsea Of Overselling Drug's Potential
• Pharma Groups Urge CMS Not To Limit Drug Price Calculation
• FDA Finalizes Regs On Device Info Requests
• Citing Prometheus, Judge Invalidates 'Abstract' ABL Patents
• 5th Circ. Health Law Challengers Indignant Over AG Letter
• JOBS Act — A Game Changer For Emerging Growth Cos.
• Illumina Backed By Advisory Firm In Roche Proxy Fight
• 2 Cases Remanded To State Court From GSK Avandia MDL
• Antitrust Challenges To FDA Citizen Petitions: Part 1
• Lilly Escapes Dozens Of Darvocet, Darvon MDL Suits
• FDA Panel Backs Astellas Bladder Drug Despite Concerns
• Sunshine Act Authors Pressure CMS For Final Rule By June
• AstraZeneca Claims FDA Skirted Seroquel Exclusivity
• US Trustee Slams Releases In Graceway Ch. 11 Plan
• Mylan Generic Treads On AstraZeneca Patents, Fed. Circ. Hears
• Mylan Aims To Nix FDA Approval Of Teva's Generic Provigil
• Holder Defends Obama's Comments On High Court To Judge
• AR Holdings Claims Par Pharma Infringed Gout Drug Patent
• Spectrum To Pay $206M For Cancer Drug Manufacturer
• Case Study: Kendall V. Hoffman-LaRoche
• Predictive Coding — Cost Savings If Investment Is Made
• Covidien's $300M Oridion Buy Latest In Shopping Spree
• Senate Drafts Plan To Speed Up FDA Drug Approval
• SEC Sticks To Tough Stance On SOX Clawback Provision
• FDA Must Do More To Ensure Drug Import Safety, Report Says
• Endo Cut Loose From 9 Suits In Darvocet, Darvon MDL
• Holder Backs Obama's ACA Remarks Amid 5th Circ. Flap
• St. Jude Yanks Heart Wires Over Erosion Concerns
• Teva, Cephalon Sue FDA Over Generic Provigil Exclusivity
• Reps. Tout Bill Giving Generics Cos. Leg Up On Exclusivity
• Prescription Drug Spending Ticked Up To $320B In 2011
• J&J's Levaquin Trial Win Upheld Over Jury Selection Beef
• Easing The Dissent's Concerns In Marine Polymer
• Challenging The Legality Of Copay Coupons
• UK Tells Docs To Ditch Stryker-J&J Hip Replacements
• More Fake Foreign Avastin Found, FDA Warns
• Procter & Gamble Drops Out Of Somaxon's OTC Silenor Effort
• Pharma Group Pans FDA Guidance On Off-Label Info Sharing
• American Regent Issues Another Recall Over Faulty Vials
• Tech, Life Sciences Cos. Vulnerable To Activist Takeovers
• IRS Objects To Graceway's Ch. 11 Plan Over Setoff Rights
• FDA Says Astellas' Bladder Drug Poses Heart, Liver Risks
• Akzo Nobel Escapes $421M Medicaid Kickback Suit
• Biomet Offers $280M For Johnson & Johnson Trauma Biz
• Judge Rules Allergan's Sanctura XR Patents Invalid
• K&L Gates Brings Duane Morris Pharma Pro To Pittsburgh
• Speedy FDA Drug Reviews On The Horizon
• Feds Seek To Weigh In On Pfizer Exec's 1st Circ. FCA Appeal
• Genzyme Beats Investor Suit Over Stock Plunge
• Teva Launches Generics Of Hypertension Drugs Avapro, Avalide
• Relovair Bet Fuels Glaxo's $213M Theravance Stake Buy
• Obama Says High Court Should Show Restraint On Health Law
• Judge Knocks Out Stryker Securities Fraud Class Action
• Illumina's Board Rejects $6.5B Cash Offer From Roche
• Medtronic Will Pay Investors $85M To End Off-Label Suit
• Latham Attracts IP, Life Sciences Transaction Pro From Wilson
• Class Claims Kept Intact In $100M Bayer Sex Bias Suit
• 3rd Circ. Lets Insurers Pass The Bill For Catheter-Slur Defense
• PETA Sues Merck Over Research Animals' Living Conditions
• Ex-Bristol Myers Exec Settles SEC Profit Inflation Suit
• Bayer Gets 3 False Ad Class Actions In NJ Nixed
• Bayer's $400M Cipro Payout Strangled Market, Consumers Say
• ITC To Probe Invisalign Rival's Allegedly Crooked Imports
• Federal Preemption Developments Since PLIVA V. Mensing